Real-world effectiveness of eculizumab in generalized myasthenia gravis in Japan: 1-year post-marketing surveillance data

被引：0
|
作者：
Murai, Hiroyuki [1 ]
Suzuki, Shigeaki [2 ]
Fukamizu, Yuji [3 ]
Osawa, Takehiko [3 ]
Kikui, Hidekazu [3 ]
Utsugisawa, Kimiaki [4 ]
机构：
[1] Int Univ Hlth & Welf, Dept Neurol, Otawara, Tochigi, Japan
[2] Keio Univ, Dept Neurol, Sch Med, Tokyo, Japan
[3] AstraZeneca Rare Dis, Alex Pharma GK, Tokyo, Japan
[4] Hanamaki Gen Hosp, Dept Neurol, Hanamaki, Iwate, Japan
来源：
NEUROLOGY | 2022年 / 98卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S41.009
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world experience with eculizumab in Japanese patients with myasthenia gravis: Post-marketing surveillance data
    Takahashi, M.
    Masuda, M.
    Watanabe, M.
    Fukamizu, Y.
    Osawa, T.
    Kikui, H.
    Murai, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 574 - 574
  • [2] Safety and Effectiveness of Eculizumab for Patients with Generalized Myasthenia Gravis in Japan: Interim Analysis of Post-Marketing Surveillance
    Murai, H.
    Suzuki, S.
    Hasebe, M.
    Fukamizu, Y.
    Rodrigues, E.
    Utsugisawa, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 485 - 486
  • [3] Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
    Murai, Hiroyuki
    Suzuki, Shigeaki
    Hasebe, Miki
    Fukamizu, Yuji
    Rodrigues, Ema
    Utsugisawa, Kimiaki
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [4] Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan
    Nishimura, Jun-ichi
    Kawaguchi, Tatsuya
    Ito, Shuichi
    Murai, Hiroyuki
    Shimono, Akihiko
    Matsuda, Takahisa
    Fukamizu, Yuji
    Akiyama, Hirozumi
    Hayashi, Hideo
    Nakano, Takashi
    Maruyama, Shoichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (04) : 419 - 431
  • [5] Safety and effectiveness of dupilumab in the real-world treatment of atopic dermatitis in Japan: 1-year interim analysis from a post-marketing surveillance
    Saeki, Hidehisa
    Fujita, Hiroyuki
    Suzuki, Katsuhisa
    Arima, Kazuhiko
    JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2023, 6 (03) : 78 - 87
  • [6] Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance (vol 14, pg 1, 2021)
    Murai, H.
    Suzuki, S.
    Hasebe, M.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [7] The real-world use of istradefylline for Parkinsons disease: Post-marketing surveillance of safety and effectiveness in Japan
    Takahashi, Makio
    Itou, Satoru
    Horiguchi, Shuji
    Tsuji, Yukie
    NEUROLOGY, 2022, 98 (18)
  • [8] TWO-YEAR POST-MARKETING SAFETY EXPERIENCE OF ECULIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN THE UNITED STATES
    Muley, S.
    Muppidi, S.
    Levine, T.
    Rodrigues, E.
    Carrillo-Infante, C.
    Howard, J.
    MUSCLE & NERVE, 2020, 62 : S113 - S114
  • [9] Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis
    Tokuyasu, Daiki
    Suzuki, Shigeaki
    Uzawa, Akiyuki
    Nagane, Yuriko
    Masuda, Masayuki
    Konno, Shingo
    Kubota, Tomoya
    Samukawa, Makoto
    Sugimoto, Takamichi
    Ishizuchi, Kei
    Oyama, Munenori
    Yasuda, Manato
    Akamine, Hiroyuki
    Onishi, Yosuke
    Suzuki, Yasushi
    Kawaguchi, Naoki
    Minami, Naoya
    Kimura, Takashi
    Takahashi, Masanori P.
    Murai, Hiroyuki
    Utsugisawa, Kimiaki
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (05): : 1338 - 1346
  • [10] REAL-WORLD EXPERIENCE OF ECULIZUMAB FOR MYASTHENIA GRAVIS
    Suh, J.
    Clarke, V.
    Guidon, A.
    MUSCLE & NERVE, 2020, 62 : S119 - S119
12345